0000899243-22-020078.txt : 20220531 0000899243-22-020078.hdr.sgml : 20220531 20220531100210 ACCESSION NUMBER: 0000899243-22-020078 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220531 FILED AS OF DATE: 20220531 DATE AS OF CHANGE: 20220531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fuhrman Alan CENTRAL INDEX KEY: 0001303521 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 22980997 MAIL ADDRESS: STREET 1: C/O AMBIT BIOSCIENCES CORPORATION STREET 2: 11080 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001651431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364813934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 978-503-2124 MAIL ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-31 1 0001651431 Checkmate Pharmaceuticals, Inc. CMPI 0001303521 Fuhrman Alan C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 1 0 0 0 Stock Option (Right to Buy) 3.93 2022-05-31 4 D 0 246671 D 2031-10-27 Common Stock 246671 0 D Stock Option (Right to Buy) 6.27 2022-05-31 4 D 0 10030 D 2031-06-16 Common Stock 10030 0 D Stock Option (Right to Buy) 2.62 2022-05-31 4 D 0 22736 D 2029-06-12 Common Stock 22736 0 D At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. /s/ Kleem Chaudhary, attorney-in-fact 2022-05-31